1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer
2024) In Journal of Medicinal Chemistry(
- Contribution to journal › Article
- 2023
-
Mark
Resistance to anti-PD-1/anti-PD-L1 : galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1
(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor : a single- and multiple-dose first-in-human study in healthy participants
(
- Contribution to journal › Article
- 2022
-
Mark
Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease
(
- Contribution to journal › Article
-
Mark
Galectin-3 inhibitor GB0139 protects against acute lung injury by inhibiting neutrophil recruitment and activation
(
- Contribution to journal › Article
- 2021
-
Mark
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis
(
- Contribution to journal › Article
- 2019
-
Mark
An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade
(
- Contribution to journal › Article
- 2016
-
Mark
A Selective Galactose–Coumarin-Derived Galectin-3 Inhibitor Demonstrates Involvement of Galectin-3-glycan Interactions in a Pulmonary Fibrosis Model
(
- Contribution to journal › Article
-
Mark
Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition
(
- Contribution to journal › Article
- 2014
-
Mark
Design, synthesis, And applications of galectin modulators in human health
(
- Chapter in Book/Report/Conference proceeding › Book chapter